Is Zimmer Biomet Stock Underperforming the Nasdaq? As Zimmer Biomet has lagged behind the broader Nasdaq Composite over the past year, Wall Street analysts remain cautious about the stock’s prospects. Barchart · Sep 16
Earnings Preview: What To Expect From Zimmer Biomet’s Report Here’s what analysts are expecting out of Zimmer Biomet’s upcoming Q2 earnings report. Barchart · Jul 22
Medical device maker Zimmer Biomet to hire 500 employees in 3 years for tech centre in India Medical device giant Zimmer Biomet is set to significantly expand its Indian footprint by hiring 500 professionals over three years for its new Bengaluru technology hub. Focusing on AI, software engineering, and R&D, the company aims to drive innovation in orthopedic implants and surgical devices. This move underscores India's growing… The Economic Times · Jul 2
Is Zimmer Biomet Stock Underperforming the S&P 500? Zimmer Biomet has lagged the broader S&P 500 Index over the past year, and analysts remain on the sidelines as they weigh the company's steady fundamentals against its modest growth outlook. Barchart · Jun 15
What Are Wall Street Analysts' Target Price for Zimmer Biomet Stock? As Zimmer Biomet has lagged behind the broader market over the past year, Wall Street analysts maintain a cautious outlook on the stock’s prospects. Barchart · May 15
Zimmer Biomet’s Quarterly Earnings Preview: What You Need to Know Zimmer Biomet is poised to report its first-quarter results in the near future, and Wall Street anticipates a measured, single-digit increase in earnings. Barchart · Apr 10
How Is Zimmer Biomet Holdings’ Stock Performance Compared to Other Medical Devices Stocks? Zimmer Biomet Holdings stock has lagged other medical device stocks over the past year, while analysts are neutral about its prospects. Barchart · Mar 16
A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBH With after-tax profits surging by close to 50% year-over-year, AstraZeneca emerges as a potential winner among healthcare names reporting earnings this month. MarketBeat · Feb 12
Zimmer Biomet Stock: Is Wall Street Bullish or Bearish? Zimmer Biomet has trailed the broader market over the past year, and it continues to face skeptical sentiment from analysts regarding its near- to medium-term growth outlook. Barchart · Feb 11
EU Mulls Tariffs and Market Restrictions on US in Response to Greenland Threat EU considers $108B in tariffs and market restrictions on the U.S. after Trump's Greenland threats, raising trade tensions. International Business Times · Jan 19
Zimmer Biomet’s Q3 2025 Earnings: What to Expect Zimmer Biomet is poised to report its fourth-quarter results in the near future, and Wall Street anticipates a measured, single-digit increase in earnings. Barchart · Jan 13
Zimmer Biomet Stock: Is ZBH Underperforming the Health Care Sector? Despite Zimmer Biomet's underperformance relative to the broader healthcare sector over the past year, the stock is still viewed by analysts with moderate optimism. Barchart · Dec 10, 2025
Zimmer Biomet Stock: Analyst Estimates & Ratings Zimmer Biomet has significantly underperformed the broader market and other medical device stocks over the past year, yet analysts remain optimistic about the stock’s prospects. Barchart · Nov 12, 2025
Zimmer Biomet Earnings Preview: What to Expect Zimmer Biomet is set to post its third-quarter results next month, and analysts project a single-digit earnings rise. Barchart · Oct 13, 2025
Barchart · Sep 17, 2025 Is Zimmer Biomet Stock Underperforming the Dow? Although Zimmer Biomet has lagged behind the Dow over the past year, analysts remain moderately optimistic about the stock’s prospects.
Evening Standard · Aug 12, 2025 Review launched over reports of delayed response to faulty knee replacement part BBC’s File on 4 said patients were left immobile and addicted to painkillers due to issues with the joint replacement.
Benzinga · Aug 7, 2025 Zimmer Biomet's $2.08 Billion Q2 Sales Ignite Orthopedic Surge, Boosts Guidance Outlook Zimmer Biomet Holdings, Inc. (NYSE:ZBH) reported second-quarter adjusted earnings of $2.07 per share, up 3% year over year, beating the Street estimates of $1.99.
Benzinga · Jul 14, 2025 Zimmer Biomet To Lead Orthopedic Robotics With Monogram's AI Tech Zimmer Biomet Holdings, Inc. (NYSE:ZBH) on Monday agreed to acquire Monogram Technologies Inc. (NASDAQ:MGRM) for an upfront payment of $4.04 per share, corresponding to an equity value of approximately $177 million and an enterprise value of approximately $168 million.
Barchart · Apr 16, 2025 Zimmer Biomet Hits 34th 52-Week Low: Value Play or Value Trap? Zimmer Biomet hit its 34th 52-week low on Tuesday. Its shares have decreased by over 20% in the past year. Trading at just 11.8x the 2025 EPS estimate, the maker of orthopedic medical devices looks cheap.
Barchart · Mar 24, 2025 Is Zimmer Biomet Stock Outperforming the S&P 500? Zimmer Biomet has recently surged past the S&P 500 Index, with analysts maintaining a cautiously upbeat outlook on its growth potential.
Barchart · Mar 16, 2025 1 Stock to Buy ASAP to Cash in on the Pickleball Craze As pickleball injuries rise, this medical device stock is perfectly positioned to cash in on the sport’s booming popularity.
Barchart · Feb 14, 2025 Are Wall Street Analysts Predicting Zimmer Biomet Stock Will Climb or Sink? Despite trailing the broader market over the past year, Zimmer Biomet still holds a moderately favorable outlook among analysts.
Barchart · Dec 18, 2024 How Is Zimmer Biomet Holdings' Stock Performance Compared to Other Medical Device Stocks? Zimmer Biomet Holdings has significantly underperformed other medical device stocks over the past year, yet analysts remain optimistic about the stock’s prospects.
MarketBeat · Dec 12, 2024 2 Robotic Surgery Stocks Challenging Intuitive Surgical's Lead Medtronic (MDT) and Zimmer Biomet (ZBH) are emerging as serious contenders in robotic surgery, challenging Intuitive Surgical’s (ISRG) market dominance.
Barchart · Nov 21, 2024 Is Wall Street Bullish or Bearish on Zimmer Biomet Stock? While Zimmer Biomet has lagged behind the broader market over the past year, analysts continue to hold a moderately positive view on the stock's prospects.